Delta Sleep-Inducing Peptide (DSIP)
Contents
Delta Sleep-Inducing Peptide (DSIP)
DSIP (Delta Sleep Inducing Peptide) also known as emideltide is a peptide comprised of a short chain of 9 amino acids. Its primary research application is in inducing deep sleep, which is characterized by delta waves seen on an electroencephalogram (EEG). It was first discovered in the brain of rabbits during sleep. Similar to all other available peptides, it is synthesized (produced in a laboratory), and not derived from animals.
How Does DSIP Work?
DSIP appears to cross into the brain and CSF through active transport, where it may modulate neural activity in a state-dependent way — meaning its effects on sleep and EEG patterns can shift based on the individual’s baseline physiology. It likely influences hypothalamic–pituitary hormones, and it seems to trigger indirect opioid-like effects through met-enkephalin release. Once active, the peptide is rapidly broken down by brain and CSF peptidases, giving it a systemic clearance window of only a few minutes.
What is DSIP Used for?
DSIP is not currently approved as a prescription medication, but it has been studied in preclinical research. Areas of interest include:
- Insomina: Early research focused on the effects of DSIP in inducing deep sleep, and it is currently being investigated for that effect.
- Withdrawal symptoms (alcohol and opioids): Due to its indirect effects on the opioid system, DSIP is thought to be able to lessen the withdrawal symptoms experienced following alcohol and opioid cessation. DSIP is not thought to be addictive because it only indirectly activates the opioid system, but this effect is still being investigated to determine whether it is sufficient to reduce the adverse symptoms of withdrawal.
- Chronic pain syndromes: Similarly, its effects on the endogenous opioid system is thought to contribute to relief in people suffering from chronic pain syndrome.
Side Effects of DSIP
DSIP appears to be fairly tolerated. Side effects may include mild heart rate variability, but this side effect is not well-documented.
DSIP Dosing Protocol (for Research)
While a dosing protocol has not been definitively determined by researchers, independent researchers report that DSIP is most effective when administered below the skin by injection (subcutaneous injection). One common research/educational dosing protocol is the following:
- 1 Weeks 1-2: 0.2 (200 mcg) 30-60 minutes before bed
- 1 Weeks 3 and beyond: 0.5 (500 mcg) 30-60 minutes before bed
Recommended DSIP Source (for Research)